"Supporters bill #MFN as a way to cut costs. In reality, it would import Europe’s system of government-set prices, and with it the predictable consequences: fewer available treatments, longer waits and stalled medical innovation." thewellnews.com/opinions/most-…

"Europe’s retreat from biomedical innovation did not occur in a vacuum, and neither would America’s. As the West throttles its science, China is racing ahead." dcjournal.com/america-cant-w…

"If policymakers are serious about reducing healthcare costs, they need to start with an honest assessment: America has a healthcare cost problem – not just a drug cost problem." linkedin.com/pulse/its-time…

"For too long, foreign competitors such as China have had a viselike grip on the global biopharmaceutical supply chain." washingtontimes.com/news/2025/nov/…

"#PBMs and their affiliates decide which drugs patients can access, how cost-sharing is designed, and how much of a manufacturer’s discount actually reaches the consumer. Spoiler: Very little does." dcjournal.com/we-cant-have-l…

"This bipartisan legislation is a decisive step toward making the prescription drug market easier to navigate for both patients and pharmacies." #ICYMI: Senator Mike Crapo and Ron Wyden are re-introducing federal #PBM reform efforts. Read more: finance.senate.gov/ranking-member…

The Trump Administration laid out a plan to set maximum fair prices for the IPAY 2027 selected drugs, cautioning that such price controls could harm patients and reduce innovation. We Work For Health responded: weworkforhealth.org/post/we-work-f…

"The evidence remains clear: the hepatitis B birth dose is safe and an essential component in helping children develop immunity against a serious, potentially lifelong disease." We know vaccines work: aap.org/en/news-room/n…

Congress is now considering legislation to bring greater transparency and accountability to PBMs. The House PBM Reform Act (HR 4317) and the Senate PBM Price Transparency and Accountability Act would change how PBMs are allowed to operate in Medicare: ncpa.org/newsroom/execu…

Happy Holidays from the We Work for Health Washington team!

"The ethical obligation of physicians to advocate for patient welfare is stymied by a system that prioritizes short-term financial gains at the expense of patient experience and access to care." Congress: #PBM reform can't wait. spokesman.com/stories/2025/d…

"Codifying #MFN into law -- and locking in sweeping government price controls -- would trigger shortages today and choke off the breakthroughs of tomorrow." Instead, #PBM reform addresses middle men directly: realclearpolicy.com/articles/2025/…

"For the U.S. to keep this economic engine humming and ensure access to lifesaving treatments and cures for patients, forward-thinking public policy is essential." Read about state-level efforts to remain competitive in the biopharma space: binje.com/op-ed-how-n-j-…

"Europe's system of drug price controls comes with serious problems, including reduced innovation and access to new medicines. Importing price controls would be one of the biggest policy mistakes the U.S. government could make." usnews.com/opinion/articl…

"Politicians in both parties long complained about this foreign free-riding, which disproportionately shifts the burden of paying for drug research and development onto Americans. That was all they did: complain." #MFN won't work for American industries: washingtontimes.com/news/2026/jan/…

"Of the investors surveyed, 87% said federal price setting policies such as Most Favored Nation would reduce U.S. biotech investment." #MFN is bad for American businesses: incubatecoalition.org/post/incubate-…

Affordability is the #1 problem in health care. By 2032, families could spend 40% of their income on health insurance while insurers demand more subsidies. Hear #RareDisease patient Sarah's story #HealthInsurance #InsuranceReformNow #CompetitionMatters

Insurance barriers are no longer neutral tools; they are profit levers. Prior authorization and restrictive formularies delay care and restrict access. Sabrina shares her story navigating denials and appeals for her two #RareDisease children. #PriorAuthDelays #InsuranceBarriers

Patients know: rising insurance costs—not better care—are driving today’s affordability crisis. RealClearHealth lays out why insurance pricing and accountability must be the focus of reform: realclearhealth.com/articles/2026/… #HealthCareAffordability #InsuranceReform #PatientFirst

"China has made staggering progress in the past decade. It now leads in synthetic biology research and is barely behind the United States in the number of clinical trials conducted. Unfortunately, Washington isn’t doing much to fight back." dcjournal.com/biotech-is-the…